Sanaria Inc.

Sanaria's primary goal is to develop and commercialize a metabolically active, non-replicating (attenuated or weakened) malaria sporozoite vaccine against Plasmodium falciparum, the malaria parasite responsible for more than 95% of malaria associated severe illness and death world-wide and the malaria parasite for which there is the most significant drug resistance. Sanaria has developed the capacity to manufacture and assay malaria parasites and mosquitoes in a highly regulated, cGMP compliant, industrial setting. These parasites, mosquitoes, and assay services are now available to the general research community through its Sanaria� Family of Products and Services.